Now live: Pro — the full 13F research suite for serious investorsSee pricing →
M28 Capital Management LP

Q4 2024 · 13F-HR

M28 Capital Management LPholdings as filed

Filed 2025-02-13 · accession 0000902664-25-000931

$101.9M
Reported value
11
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
Y95308105WVEWAVE LIFE SCIENCES LTD$70.1M68.8%5,664,548CommonSOLE
88322Q108TGTXTG THERAPEUTICS INC$4.9M4.78%161,600CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$4.8M4.76%385,680CommonSOLE
00534A102IVVDINVIVYD INC$4.1M4.02%9,248,250CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$4.0M3.92%110,400CommonSOLE
35168W103GUTSFRACTYL HEALTH INC$3.8M3.75%1,856,117CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$3.3M3.27%121,200CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$2.7M2.65%1,019,498CommonSOLE
231269309CRISCURIS INC$1.6M1.57%521,059CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$1.3M1.25%185,100CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$1.3M1.24%67,400CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.